SPY301.63-1.34 -0.44%
DIA252.78-1.57 -0.62%
IXIC9,375.03+6.04 0.06%

Piper Sandler Downgrades Marker Therapeutics to Neutral, Lowers Price Target of $2.5

Piper Sandler analyst Edward Tenthoff downgrades Marker Therapeutics (NASDAQ:MRKR) from Overweight to Neutral and lowers the price target from $5 to $2.5.

Benzinga · 05/12/2020 09:48

Piper Sandler analyst Edward Tenthoff downgrades Marker Therapeutics (NASDAQ:MRKR) from Overweight to Neutral and lowers the price target from $5 to $2.5.